Every 8-K that AbbVie Inc. (ABBV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ABBV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABBV filings page.
AbbVie Inc. (ABBV) announced completion of its acquisition of Apogee Therapeutics, Inc. for $135.11 per share in cash, implying a total equity value of approximately $10.9 billion, adding late-stage and early-stage immunology assets focused on atopic dermatitis, asthma and COPD. Apogee is now part of AbbVie.
Apogee’s lead drug candidate zumilokibart (APG777), a half‑life extended IL‑13 monoclonal antibody for atopic dermatitis, showed in a Phase 2 trial that about two‑thirds of patients achieved significant skin clearance at 16 weeks, with sustained control enabling quarterly or twice‑yearly dosing, and a favorable safety profile. Combination candidate APG273, which includes an antibody blocking TSLP, is being developed for asthma with data supporting long‑acting dosing.
AbbVie expects the acquisition to reduce adjusted diluted EPS by $0.14 in 2026 and about $0.46 in 2027, with accretion beginning in 2032, but is reaffirming its 2026 full‑year adjusted diluted EPS guidance range of $13.87–$14.07 and third‑quarter 2026 adjusted diluted EPS guidance of $3.84–$3.88. The 2026 EPS outlook includes an unfavorable $0.58 per share impact from acquired IPR&D and milestones recorded through the second quarter.
AbbVie Inc. (ABBV) completed an underwritten public offering of multiple series of unsecured, unsubordinated senior notes to help finance its previously announced acquisition of Apogee Therapeutics, Inc. The offering includes $500,000,000 senior floating rate notes due 2028 and eight series of fixed-rate notes.
The fixed-rate series comprise $1,000,000,000 of 4.500% notes due 2028, $1,250,000,000 of 4.650% notes due 2030, $1,500,000,000 of 4.875% notes due 2031, $1,250,000,000 of 5.050% notes due 2033, $1,500,000,000 of 5.300% notes due 2036, $1,000,000,000 of 5.450% notes due 2038, $1,500,000,000 of 6.000% notes due 2056 and $500,000,000 of 6.100% notes due 2066.
The floating rate notes and 4.500% 2028 notes mature on August 18, 2028; the 2030 notes mature on March 15, 2030; all other fixed-rate series mature on September 15 of their stated year. AbbVie expects to use the net proceeds primarily to pay a portion of the cash consideration to Apogee shareholders and related fees, with any remainder for general corporate purposes. If the Apogee acquisition is not pursued or the definitive agreement is terminated, AbbVie must redeem all notes maturing between 2028 and 2038 at 101% of principal plus accrued interest under a special mandatory redemption.
AbbVie Inc. entered into an underwriting agreement with Morgan Stanley, BofA Securities, J.P. Morgan and SG Americas for multiple series of senior notes, including senior floating rate notes due 2028 and fixed-rate notes with coupons from 4.500% to 6.100% maturing between 2028 and 2066.
The offering is registered under the Securities Act, with closing expected on August 18, 2026, subject to customary conditions. AbbVie expects approximately $9.93 billion in net proceeds and intends to use them to fund part of its Apogee Therapeutics acquisition, pay related costs, for other general corporate purposes, and the net proceeds will reduce commitments under its $10.0 billion 364-day delayed draw term loan facility.
AbbVie reported strong second‑quarter 2026 results, with net revenues of $16.990 billion, up 10.2 percent on a reported basis, and GAAP diluted EPS of $2.03, up 290.4 percent. Adjusted diluted EPS was $3.65, an increase of 22.9 percent, including a $0.17‑per‑share unfavorable impact from acquired IPR&D and milestones expense. The adjusted operating margin reached 48.3 percent, versus a GAAP operating margin of 37.9 percent.
Growth was led by immunology and neuroscience. Immunology revenues rose to $8.786 billion, driven by Skyrizi at $5.505 billion and Rinvoq at $2.525 billion, while Humira declined to $756 million. Neuroscience revenues grew to $3.228 billion, with Vraylar at $1.071 billion and Botox Therapeutic at $1.042 billion. Oncology revenues were $1.650 billion, modestly lower, as Venclexta grew but Imbruvica declined.
AbbVie also announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion in equity value to expand its immunology pipeline. Adjusted diluted EPS guidance for full‑year 2026 was updated from $13.91–$14.11 to $13.87–$14.07, incorporating an expected $0.14‑per‑share dilutive impact from the proposed Apogee acquisition, partially offset by $0.10 of overperformance.
AbbVie Inc. updated its 2026 earnings guidance to reflect second-quarter 2026 acquired IPR&D and milestones expense of $291 million, which is expected to reduce reported GAAP and adjusted non-GAAP diluted EPS by $0.17 per share. The company now expects full-year 2026 adjusted diluted EPS of $13.91–$14.11, compared with previously announced guidance that excluded this second-quarter expense. For the quarter ended June 30, 2026, AbbVie’s adjusted diluted EPS guidance range is $3.57–$3.61, also including the impact of the same $291 million expense. These figures are preliminary and subject to completion of regular financial closing procedures.
AbbVie Inc. is expanding its immunology and respiratory portfolio by agreeing to acquire Apogee Therapeutics and its pipeline of clinical-stage antibody drugs. AbbVie will purchase all outstanding Apogee shares for $135.11 in cash per share, valuing the company at about $10.9 billion. The deal, unanimously approved by both boards, is expected to close in the third quarter of 2026, subject to Apogee shareholder and regulatory approvals.
Apogee’s lead asset, zumilokibart (APG777), has shown strong Phase 2 results in atopic dermatitis, with roughly two-thirds of treated patients achieving significant skin clearance at 16 weeks and supporting infrequent maintenance dosing. AbbVie expects the transaction to be accretive to its adjusted diluted earnings per share beginning in 2032 and highlights potential “mega-blockbuster” peak sales across Apogee’s pipeline, including combination program APG273 for asthma.
AbbVie Inc. reported the results of its 2026 Annual Meeting of Stockholders, held on May 8, 2026. Stockholders voted on the election of directors and several other matters.
Director nominees including Jennifer L. Davis, Melody B. Meyer, Robert A. Michael, and Frederick H. Waddell each received more than 1.21 billion votes in favor, with substantially fewer votes against or abstaining, alongside significant broker non-votes. Additional proposals received vote totals such as 1,522,575,012 for and 23,766,564 against on one item, and other items with for votes ranging from about 515.6 million to over 1.29 billion, all with recorded against, abstain, and broker non-vote counts.
AbbVie reported strong first-quarter 2026 results, with worldwide net revenues of $15.002 billion, up 12.4% year over year on a reported basis (10.3% operational). Growth was driven by immunology and neuroscience, while oncology was flat and aesthetics grew modestly.
Immunology net revenues were $7.290 billion, up 16.4%, led by Skyrizi at $4.483 billion and Rinvoq at $2.119 billion, which more than offset a 38.6% decline in Humira to $688 million. Neuroscience net revenues rose 26.0% to $2.875 billion, with Botox Therapeutic at $1.009 billion and combined Ubrelvy/Qulipta at $635 million.
On a GAAP basis, diluted EPS was $0.39, down 45.8%, while adjusted diluted EPS rose 7.7% to $2.65, including an unfavorable $0.41 per-share impact from acquired IPR&D and milestones expense. AbbVie raised its full-year 2026 adjusted EPS guidance to a range of $14.08–$14.28.
AbbVie Inc. updated its 2026 earnings guidance to reflect a sizeable first-quarter charge for acquired in-process R&D and milestones. The company expects to record $744 million of pre-tax acquired IPR&D and milestones expense in the first quarter of 2026, which is estimated to reduce both GAAP and adjusted diluted earnings per share by $0.41.
Including this impact, AbbVie now guides full-year 2026 adjusted diluted EPS to a range of $13.96 to $14.16, compared with prior guidance that excluded this expense. First-quarter 2026 adjusted diluted EPS guidance, including the charge, is $2.56 to $2.60, down from the previously announced range of $2.97 to $3.01 that did not include the IPR&D and milestones expense.
AbbVie Inc. completed an underwritten public offering of multiple series of senior unsecured notes. The company issued senior floating rate notes due 2028 with an aggregate principal amount of $750,000,000, along with several series of fixed-rate senior notes maturing between 2028 and 2066.
The fixed-rate series include $1,500,000,000 of 3.775% notes due 2028, $1,250,000,000 of 4.125% notes due 2031, $1,250,000,000 of 4.400% notes due 2033, $1,500,000,000 of 4.750% notes due 2036, $1,250,000,000 of 5.550% notes due 2056, and $500,000,000 of 5.650% notes due 2066. All notes rank equally with AbbVie’s other unsecured, unsubordinated obligations.
The notes were issued under an existing shelf registration and an indenture that includes customary covenants, such as limits on certain liens and restrictions on mergers or transfers of substantially all assets. AbbVie has various optional redemption rights, including make-whole redemptions and par calls after specified dates for each longer-dated series.
AbbVie Inc. entered into an underwriting agreement to issue and sell multiple series of senior notes with expected net proceeds of approximately $7.95 billion. The transaction includes floating rate notes due 2028 and fixed-rate notes maturing between 2028 and 2066.
AbbVie plans to use the proceeds to repay amounts outstanding under a $4.0 billion 364-day delayed draw term loan facility maturing in May 2026, of which $2.0 billion is currently outstanding, and for general corporate purposes, which may include repayment or repurchase of other outstanding debt.
AbbVie Inc. filed a current report stating that it issued a press release with its financial results for the fourth quarter and full year ended December 31, 2025. The company released these results on February 4, 2026, and attached the full press release as Exhibit 99.1.
The filing is presented under the Results of Operations and Financial Condition section, indicating the update relates to AbbVie’s operating performance and overall financial health for 2025. Detailed figures and metrics are contained in the referenced press release rather than in this summary document.
AbbVie Inc. updated its earnings outlook to reflect a large research and development charge in the fourth quarter of 2025. The company expects acquired in-process R&D and milestones expense of $1.3 billion on a pre-tax basis, which is estimated to reduce both GAAP diluted EPS and adjusted non-GAAP diluted EPS by $0.71 per share for the quarter.
Including this fourth quarter expense, AbbVie now expects its full-year 2025 adjusted diluted EPS to be in the range of $9.90–$9.94. For the fourth quarter of 2025, adjusted diluted EPS is guided to a range of $2.61–$2.65. The company notes that results for the quarter ended December 31, 2025 are preliminary and subject to completion of its financial closing procedures.
AbbVie Inc. (ABBV) filed an 8-K announcing Q3 2025 results. The company issued a press release for the third quarter ended September 30, 2025, and furnished it with this report.
The press release is included as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition). No financial figures are detailed in this report itself.
AbbVie Inc. filed a Form 8-K to update investors on how acquired in-process research and development (IPR&D) and milestone expenses will affect its 2025 earnings. For the third quarter of 2025, AbbVie expects to record $2.7 billion of acquired IPR&D and milestones expense on a pre-tax basis, which it says will have an unfavorable impact of $1.50 on both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. The company notes that results for the quarter ended September 30, 2025 are still preliminary and may change.
AbbVie reiterates that it does not forecast acquired IPR&D and milestones expense because the timing and occurrence of such transactions are uncertain, and prior 2025 guidance excluded these expenses beyond the second quarter. Including the third quarter 2025 acquired IPR&D and milestones expense, AbbVie now provides a full-year 2025 adjusted diluted earnings per share guidance range of $10.38 to $10.58, and a third quarter 2025 adjusted diluted earnings per share guidance range of $1.74 to $1.78.
AbbVie Inc. reported that it has settled litigation with all generic drug manufacturers that filed abbreviated new drug applications in the United States for generic versions of its upadacitinib tablets, marketed as RINVOQ. Based on these settlement and license agreements, and assuming pediatric exclusivity is granted, AbbVie does not expect any generic upadacitinib tablet products to enter the U.S. market before April 2037, subject to standard acceleration provisions in the agreements.
The company also reiterated that these expectations are forward-looking and could be affected by factors such as intellectual property challenges, litigation outcomes, regulatory changes, and broader business risks described in its prior annual and quarterly reports.